BriaCell Therapeutics Slide After Equity Offer

Dow Jones

Jul 16, 2025

By Josh Beckerman

BriaCell Therapeutics shares slipped after the company announced a $15 million equity offering.

The stock was recently down 62%, to 78 cents, on the Nasdaq late Tuesday. Shares were between $1.75 and $1.90 for much of the trading day before BriaCell reported the offering.

The cancer-focused biotechnology company said it was offering 12 million units for $1.25 each. Each unit consists of one common share, or pre-funded warrant in lieu thereof, and one warrant.

Earlier Tuesday, BriaCell said Mayo Clinic was added to a continuing clinical study evaluating BriaCell's lead drug candidate, Bria-IMT, in advanced metastatic breast cancer.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

July 15, 2025 15:41 ET (19:41 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2551919496"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2551919496\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2551919496?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-16 03:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551919496","market":"other","top_or_hot":-1,"title":"BriaCell Therapeutics Slide After Equity Offer","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  BriaCell <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares slipped after the company announced a $15 million equity offering. \n</p>\n<p>\n  The stock was recently down 62%, to 78 cents, on the <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> late Tuesday. Shares were between $1.75 and $1.90 for much of the trading day before BriaCell reported the offering. \n</p>\n<p>\n  The cancer-focused biotechnology company said it was offering 12 million units for $1.25 each. Each unit consists of one common share, or pre-funded warrant in lieu thereof, and one warrant. \n</p>\n<p>\n  Earlier Tuesday, BriaCell said Mayo Clinic was added to a continuing clinical study evaluating BriaCell's lead drug candidate, Bria-IMT, in advanced metastatic breast cancer. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 15, 2025 15:41 ET (19:41 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BriaCell Therapeutics Slide After Equity Offer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBriaCell Therapeutics Slide After Equity Offer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-16 03:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  BriaCell <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares slipped after the company announced a $15 million equity offering. \n</p>\n<p>\n  The stock was recently down 62%, to 78 cents, on the <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> late Tuesday. Shares were between $1.75 and $1.90 for much of the trading day before BriaCell reported the offering. \n</p>\n<p>\n  The cancer-focused biotechnology company said it was offering 12 million units for $1.25 each. Each unit consists of one common share, or pre-funded warrant in lieu thereof, and one warrant. \n</p>\n<p>\n  Earlier Tuesday, BriaCell said Mayo Clinic was added to a continuing clinical study evaluating BriaCell's lead drug candidate, Bria-IMT, in advanced metastatic breast cancer. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 15, 2025 15:41 ET (19:41 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2551919496","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551919496","pubTimestamp":1752608460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"BriaCell Therapeutics shares slipped after the company announced a $15 million equity offering.The stock was recently down 62%, to 78 cents, on the Nasdaq late Tuesday. Shares were between $1.75 and $1.90 for much of the trading day before BriaCell reported the offering.The cancer-focused biotechnology company said it was offering 12 million units for $1.25 each. Each unit consists of one common share, or pre-funded warrant in lieu thereof, and one warrant.Earlier Tuesday, BriaCell said Mayo Clinic was added to a continuing clinical study evaluating BriaCell's lead drug candidate, Bria-IMT, in advanced metastatic breast cancer.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","EQR":"资产住宅公司","BK4139":"生物科技","BK4588":"碎股","BCTX":"BriaCell Therapeutics Corp.","BK4585":"ETF&股票定投概念","BK4215":"住宅房地产投资信托","BK4007":"制药","LENZ":"Therapeutics"},"translate_title":"BriaCell Therapeutics在股权发行后股价下滑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"BCTX":1,"EQR":1},"content_text":"By Josh Beckerman \n\n\n \n\n\n  BriaCell Therapeutics shares slipped after the company announced a $15 million equity offering. \n\n\n  The stock was recently down 62%, to 78 cents, on the Nasdaq late Tuesday. Shares were between $1.75 and $1.90 for much of the trading day before BriaCell reported the offering. \n\n\n  The cancer-focused biotechnology company said it was offering 12 million units for $1.25 each. Each unit consists of one common share, or pre-funded warrant in lieu thereof, and one warrant. \n\n\n  Earlier Tuesday, BriaCell said Mayo Clinic was added to a continuing clinical study evaluating BriaCell's lead drug candidate, Bria-IMT, in advanced metastatic breast cancer. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 15, 2025 15:41 ET (19:41 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}